The latest developmental drugs, particularly for use in oncology, rely on the targeted degradation of harmful pathogenic proteins. In a recent study published in Nature Chemical Biology, researchers at CeMM, the Research Center for Molecular Medicine of the Austrian Academy of Sciences, and the University of Dundee (U.K.) identify potential resistance mechanisms and provide insights on how to overcome them.